New Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials and Real-World Analyses Shed Light on Link Between Thyroid Autoimmunity and Hearing Risks

Horizon Therapeutics plc today announced the presentation of a series of analyses demonstrating the risk of hearing-related events among people with Graves’ disease and TED, including among... | June 17, 2023

Related Keywords

Chicago ,Illinois ,United States ,Michigan ,American ,Terry Smith ,Jeffreyw Sherman ,European Group On Grave Orbitopathy ,Wk Kellogg Eye Center ,Nasdaq ,Endocrine Society Annual Meeting ,Exchange Commission ,Instagram ,Department Of Ophthalmology ,University Of Michigan Medical School ,Facebook ,Visa ,Twitter ,Endocrine Society ,Linkedin ,Drug Administration ,American Association Of Clinical Endocrinology Annual Meeting ,Horizon Therapeutics ,American Association ,Clinical Endocrinology Annual Meeting ,Professor Emeritus ,Visual Sciences ,Eye Center ,Michigan Medical ,Thyroid Eye Disease ,Hearing Related Events Improved During ,Endocrine Practice ,Grave Ophthalmopathy Quality ,Related Events ,Large Historical Cancer ,Thyroid Eye ,Inflammatory Bowel Disease ,Full Prescribing Information ,United States Securities ,Issues Associated ,Grave Disease ,Annual Meeting ,Related Adverse Events ,Life Assessments ,Thyroid Eye Disease Patients Treated ,Teprotumumab Oncology Clinical ,Thyroid Associated ,Grave Disease Is Mediated Through ,Insulin Like Growth Factor ,Grave Orbitopathy ,Clinical Practice Guidelines ,Medical Management ,European Group ,